Last reviewed · How we verify

Pentetate Calcium Trisodium — Competitive Intelligence Brief

Pentetate Calcium Trisodium (PENTETATE CALCIUM TRISODIUM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pentetate calcium trisodium. Area: Nephrology.

marketed pentetate calcium trisodium Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Pentetate Calcium Trisodium (PENTETATE CALCIUM TRISODIUM) — Hameln. Pentetate Calcium Trisodium works by binding to radioactive ions, such as Americium, Curium, and Plutonium, to facilitate their excretion from the body.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pentetate Calcium Trisodium TARGET PENTETATE CALCIUM TRISODIUM Hameln marketed pentetate calcium trisodium 2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pentetate calcium trisodium class)

  1. Hameln · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pentetate Calcium Trisodium — Competitive Intelligence Brief. https://druglandscape.com/ci/pentetate-calcium-trisodium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: